Nitric oxide synthase gene polymorphisms and prostate cancer risk

Kyoung Mu Lee, Daehee Kang, Sue Kyung Park, Sonja I. Berndt, Douglas Reding, Nilanjan Chatterjee, Stephen Chanock, Wen Yi Huang, Richard B. Hayes

Research output: Contribution to journalArticle

Abstract

Nitric oxide (NO) induces cytotoxicity and angiogenesis, and may play a role in prostate carcinogenesis, potentially modulated by environmental exposures. We evaluated the association of prostate cancer with genetic polymorphisms in two genes related to intracellular NO: NOS2A [inducible nitric oxide synthase (NOS); -2892T>C, Ex16 + 14C>T (S608L), IVS16 + 88T>G and IVS20 + 524G>A ] and NOS3 [endothelial NOS; IVS1 - 762C>T, Ex7 - 43C>T (D258D), IVS7 - 26A>G, Ex8 - 63G>T (E298D) and IVS15 - 62G>T ]. Prostate cancer cases (n = 1320) from the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial were frequency matched to controls (n = 1842), by age, race, time since initial screening and year of blood draw. An antioxidant score [range 3-12; low (3-7) versus high (8-12)] was created by summing the quartile levels of vitamin E, β-carotene and lycopene, which were coded from 1 to 4, respectively. The global tests for all eight single-nucleotide polymorphisms (SNPs) (excluding NOS2A -2892T>C, with low minor allele frequency) were statistically significant for prostate cancer (P = 0.005), especially for aggressive cancer (stage III-IV or Gleason score ≥ 7) (P = 0.01). The NOS2A IVS16 + 88 GT/TT was associated with increased prostate caner risk (odds ratio = 1.24, 95% confidence interval = 1.00-1.54), whereas the IVS20 + 524 AG/GG was associated with decreased risk (0.77, 0.66-0.90). The NOS3 IVS7 - 26GG was associated with increased prostate caner risk (1.33, 1.07-1.64). All these SNPs showed significant associations with aggressive cancer and not for non-aggressive cancer. In the evaluation of effect modification, the effect of the NOS2A IVS16 + 88 GT/TT on aggressive cancer was stronger among subjects with higher antioxidant intake (1.61, 1.18-2.19; Pinteraction = 0.01). Our results suggest that NOS gene polymorphisms are genetic susceptibility factors for aggressive prostate cancer.

Original languageEnglish (US)
Pages (from-to)621-625
Number of pages5
JournalCarcinogenesis
Volume30
Issue number4
DOIs
StatePublished - Apr 17 2009

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Nitric oxide synthase gene polymorphisms and prostate cancer risk'. Together they form a unique fingerprint.

  • Cite this

    Lee, K. M., Kang, D., Park, S. K., Berndt, S. I., Reding, D., Chatterjee, N., Chanock, S., Huang, W. Y., & Hayes, R. B. (2009). Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis, 30(4), 621-625. https://doi.org/10.1093/carcin/bgp028